New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.
A newer class of cholesterol lowering drugs known as PCSK9 inhibitors has emerged as an effective treatment for drastically lowering LDL cholesterol beyond current treatment targets. Earlier this year, results from a clinical trial found that the PCSK9 inhibitor evolocumab, when added to statin therapy, resulted in a significant reduction in the risk for cardiovascular events and was safe.
In a new analysis, researchers sought to explore whether there was "floor effect" in the lowering of LDL cholesterol - essentially, is there a threshold below which there would be no added clinical benefit? Additionally, researchers explored whether ultra-low LDL cholesterol levels would have any negative impact. Their findings were presented at the European Society of Cardiology Congress, and simultaneously published in The Lancet.
Using data from the FOURIER trial (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk), which found that patients treated with evolocumab and statin therapy had a 20 percent reduction in the risk of cardiovascular death, myocardial infarction or stroke, researchers examined the efficacy and safety of very low levels of LDL cholesterol among 25,982 patients per the degree of LDL-C reduction following one month of treatment.
Researchers found that the risk for cardiovascular events (including cardiovascular death, heart attack, and stroke) over 2.2 years progressively declined as LDL cholesterol levels decreased to below 20 mg/dL (0.5 mmol/L), and participants who achieved an LDL-C of less than 10 mg/dL (0.26 mmol/L) had a more than 40 percent lower risk of cardiovascular events than those with an LDL cholesterol equal to or greater than 100 mg/dL (2.6 mmol/L).
"Our findings demonstrate that there is essentially no floor effect, and that lower levels translated to a greater reduction in risk. Among high-risk patients, achieving a LDL cholesterol level far below the most common treatment target of 70 mg/dL (1.8 mmol/L) can further reduce the risk for an adverse cardiovascular event, with no major safety concerns," said a senior investigator.
report no significant association between LDL-C level and prespecified adverse events, and in sub analyses they found that very low LDL cholesterol levels did not have a negative impact on cognition, reaction time or memory. In addition to neurocognitive events, researchers looked at nine other safety endpoints and found no differences across the groups of achieved LDL-C.
"Given the previous results from the FOURIER trial and the findings from this new analysis, patients - particularly those at a high risk for future cardiovascular events - should review their LDL cholesterol with their physicians and discuss whether it could be beneficial to lower that level beyond what they have achieved with diet, lifestyle modifications and statin therapy," said the author.
Evolocumab is a fully human monoclonal antibody manufactured by Amgen that works by blocking proprotein convertase subtilisin-kexin 9 (PCSK9), a protein that reduces the liver's ability to remove LDL cholesterol from the blood. The drug, which costs approximately $14,000 annually, was approved for use in the United States in 2016 as an addition to statin therapy and lifestyle changes for lowering LDL cholesterol in some adults with cardiovascular disease.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32290-0/fulltext?elsca1=tlxpr
Latest News
Chromatin and RNA interacti…
By newseditor
Posted 18 May
Why patients with ARID1A mu…
By newseditor
Posted 18 May
Smuggling small molecule mo…
By newseditor
Posted 18 May
Men with gene mutations are…
By newseditor
Posted 17 May
B cell oxidative phosphoryl…
By newseditor
Posted 17 May
Other Top Stories
Modulation of Alzheimer-related cognitive and brain network by ovar…
Read more
How neurons process mistakes and correct our behavior
Read more
Common antidepressant does not aid stroke recovery
Read more
Why young bones repair fractures faster than the old ones?
Read more
Using graphene to detect ALS, other neurodegenerative diseases
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Immunotherapy for colorecta…
By newseditor
Posted 18 May
Single-cell multiplex chrom…
By newseditor
Posted 18 May
Autophagy preferentially de…
By newseditor
Posted 18 May
Poison Ivy, Poison Oak, and…
By newseditor
Posted 18 May
GLP-1-directed NMDA recepto…
By newseditor
Posted 18 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar